ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis

Summary

ADAMTS13 cleaves ultralarge multimeric von Willebrand Factor (VWF), thereby preventing formation of platelet-rich microthrombi. ADAMTS13 is mainly produced by hepatic stellate cells, and numerous studies have suggested a functional role of ADAMTS13 in the pathogenesis of liver diseases. The aim of our study was to investigate a potential role of ADAMTS13 in formation of hepatic microthrombi and development of non-alcoholic steatohepatitis (NASH), and furthermore to evaluate whether plasmin can compensate for the absence of ADAMTS13 in removal of thrombi. Therefore, we used a model of high-fat diet-induced steatosis in Adamts13 deficient (Adamts13^−/−) and wild-type (WT) control mice. Microthrombi were more abundant in the liver of obese Adamts13^−/− as compared to obese WT or to lean Adamts13^−/− mice. Obese Adamts13^−/− mice displayed lower platelet counts and higher prevalence of ultra-large VWF multimers. Hepatic plasmin-α2-antiplasmin complex levels were comparable for obese WT and Adamts13^−/− mice and were lower for lean Adamts13^−/− than WT mice, not supporting marked activation of the fibrinolytic system. High fat diet feeding, as compared to normal chow, resulted in enhanced liver triglyceride levels for both genotypes (p < 0.0001) and steatosis (p < 0.0001 for WT mice, p = 0.002 for Adamts13^−/− mice) without differences between the genotypes. Expression of markers of inflammation, oxidative stress, steatosis and fibrosis was affected by diet, but not by genotype. Thus, our data confirm that obesity promotes NASH, but do not support a detrimental role of ADAMTS13 in its development. However, Adamts13 deficiency in obese mice promotes hepatic microthrombosis, whereas a compensatory role of plasmin in removal of microthrombi in the absence of ADAMTS13 could not be demonstrated.

Keywords

ADAMTS13 - microthrombosis - non-alcoholic fatty liver disease - obesity

• References

• 1 Le Goff C, Cormier-Daire V. The ADAMTS(L) family and human genetic disorders. Hum Mol Genet 2011; 20: R163-167.
• 2 Fujimura Y, Matsumoto M, Yagi H. et al. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002; 75: 25-34.
• 3 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
• 4 Kokame K, Matsumoto M, Soejima K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907.
• 5 Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005; 106: 11-17.
• 6 Savasan S, Lee SK, Ginsburg D. et al. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003; 101: 4449-4451.
• 7 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
• 8 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
• 9 Tersteeg C, de Maat S, De Meyer SF. et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic micro-angiopathy. Circulation 2014; 129: 1320-1331.
• 10 Hugenholtz GC, Lisman T. Letter by Hugenholtz and Lisman regarding article, “plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy”. Circulation 2015; 131: e18.
• 11 Uemura M, Tatsumi K, Matsumoto M. et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
• 12 Uemura M, Fujimura Y, Ko S. et al. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol 2010; 91: 20-29.
• 13 Takaya H, Uemura M, Fujimura Y. et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res 2012; 42: 459-472.
• 14 Uemura M, Matsuyama T, Ishikawa M. et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multi-organ failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005; 29: 264S-271S.
• 15 Matsumoto M, Kawa K, Uemura M. et al. Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant 2007; 40: 251-259.
• 16 Ikeda H, Tateishi R, Enooku K. et al. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C. Cancer Epidemiol Biomarkers Prev 2011; 20: 2204-2211.
• 17 Watanabe N, Ikeda H, Kume Y. et al. Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis. Thromb Haemost 2009; 102: 389-396.
• 18 Geys L, Scroyen I, Roose E. et al. ADAMTS13 deficiency in mice does not affect adipose tissue development. Biochim Biophys Acta 2015; 1850: 1368-1374.
• 19 Motto DG, Chauhan AK, Zhu G. et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
• 20 Van De Craen B, Scroyen I, Vranckx C. et al. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb Res 2012; 129: e126-133.
• 21 Lijnen HR, Van Hoef B, Dewerchin M. et al. Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury. Arterioscler Thromb Vasc Biol 2000; 20: 1488-1492.
• 22 Lotta LA, Wu HM, Mackie IJ. et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120: 440-448.
• 23 Hugenholtz GC, Adelmeijer J, Meijers JC. et al. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013; 58: 752-761.
• 24 Charlton MR. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn’t there). Gastroenterology 2011; 140: 25-28.
• 25 Park EJ, Lee JH, Yu GY. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
• 26 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.